低分子肝素与阿托伐他汀钙对肝脏转氨酶的影响

Effect of low molecular weight heparin and atorvastatin calcium on hepatic transaminases

目的探讨阿托伐他汀钙和低分子肝素两药并用对肝脏转氨酶的影响。方法采用回顾性分析,抽取诊断为短暂性脑缺血发作、(急性)脑梗死、后循环缺血、椎-基底动脉供血不足、静脉窦血栓形成或下肢静脉血栓形成的患者167例。根据用药情况,将患者分为阿托伐他汀钙组、低分子肝素组及联合用药组,以肝脏转氨酶ALT、AST作为观察指标,对患者用药前后ALT、AST水平变化情况进行分析。结果阿托伐他汀钙组用药前后ALT、AST水平无明显差异,低分子肝素组、联合用药组用药后ALT、AST水平显著高于用药前(P<0.05)。低分子肝素组和联合用药组治疗后ALT、AST上升幅度和升高发生率均高于阿托伐他汀钙组;且联合用药组治疗后ALT、AST上升幅度和升高发生率高于低分子肝素组。结论低分子肝素和阿托伐他汀并用时,应密切观察肝脏转氨酶的水平,避免严重肝损事件发生。

Objective To investigate the effect of atorvastatin calcium,low-molecular weight heparin(LMWH)and the concomitant administration of the two drugs on hepatic transaminases.Methods A retrospective analysis was used.167 patients with transient cerebral ischemia,(acute)cerebral infarction,posterior circulation ischemia,insufficient blood supply of vertebra-basilar artery,cerebral venous sinus thrombosis,or venous thrombosis of lower extremities were selected from our hospital.The patients were divided into atorvastatin calcium group(AC),LMWH group,and atorvastatin calcium plus LMWH(APL)group.As hepatic transaminase indices,transaminase levels in patients before and after the medication(s)were pooled and analyzed.Results There was no significant difference between transaminase levels at pre-and post-treatments with atorvastatin.The transaminase levels in LMWH group and APL group at post-medication were significantly higher than those at pre-medication(P<0.05).Simultaneously,it was found that transaminase levels and incidence of higher transaminase levels in APL group and LMWH group were significantly higher as compared to those in AC group(P<0.05);furthermore,Transaminase levels and incidence of higher transaminase levels in APL group were also higher than LMWH group.Conclusion When LMWH is concomitantly administered with atorvastatin,transaminase levels should be closely monitered to avoid injuring patients’livers.